While our previous work demonstrated elevated baseline immune checkpoint expression in CLL B cells compared to healthy controls, it remains unclear whether the changes observed after PKC activation are unique to CLL B cells. The gene discussed is PRRT2; the disease is B-cell chronic lymphocytic leukemia.